Herbert K.
- Country
- Germany
- Department
- NA
Research Overview
- Efficacy and Safety of Sarilumab Dose Levels with a 52‑Week Prednisone Taper in Adults with Early Polymyalgia Rheumatica: Randomized Double‑Blind Placebo‑Controlled Trial
- Evaluation of the Efficacy and Safety of GLPG3667 in Adults with Active Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Tofacitinib in Early Active Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study
Data & Insights
Has run more than one trial at 92 of 239 partner sites.
Specializations
Inflammatory Arthritis
This investigator specializes in treating various forms of inflammatory joint conditions, with particular emphasis on psoriatic arthritis and its management through novel therapeutic approaches.
- Biologic DMARD treatments
- Anti-TNFα therapy outcomes
- Advanced therapeutic interventions
The research encompasses both treatment-naive patients and those with inadequate response to conventional therapies.
Rheumatic Conditions
Focused on investigating treatments for polymyalgia rheumatica and axial spondyloarthritis, exploring innovative therapeutic combinations and early intervention strategies.
- Early-stage disease management
- Combination therapy approaches
- NSAID-resistant conditions
The investigator's work addresses both conventional and emerging treatment modalities for inflammatory rheumatic diseases.
Autoimmune Disorders
Dedicated to advancing treatment options for systemic lupus erythematosus, investigating novel oral therapeutics for managing disease activity.
- Disease activity monitoring
- Innovative oral treatments
- Therapeutic efficacy assessment
The research focuses on developing effective management strategies for complex autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.